Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
Reads0
Chats0
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Reactive Oxygen Species (ROS)-Based Nanomedicine.
Bowen Yang,Yu Chen,Jianlin Shi +2 more
TL;DR: In this article, the intrinsic biochemical properties of reactive oxygen species (ROS) underlie the mechanisms that regulate various physiological functions of living organisms, and they play an essential role in regulating various physiological function.
Journal ArticleDOI
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis.
Marta Seretny,Gillian L. Currie,Emily S. Sena,Sabrina Ramnarine,Robin Grant,Malcolm R. Macleod,Leslie A. Colvin,Marie Fallon +7 more
TL;DR: A systematic review of studies reporting the prevalence of Chemotherapy‐induced peripheral neuropathy identified 31 studies with data from 4179 patients and identified a number of genetic and clinical risk factors that require further study.
Journal ArticleDOI
Microbiota: a key orchestrator of cancer therapy.
Soumen Roy,Giorgio Trinchieri +1 more
TL;DR: The evidence for the ability of the microbiota to modulate chemotherapy, radiotherapy and immunotherapy is discussed with a focus on the microbial species involved, their mechanism of action and the possibility of targeting the microbiome to improve anticancer efficacy while preventing toxicity.
Journal ArticleDOI
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Renata Zajączkowska,Magdalena Kocot-Kępska,Wojciech Leppert,Anna Wrzosek,Joanna Mika,Jerzy Wordliczek +5 more
TL;DR: A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies and the neurotoxicity mechanisms of the most common antineoplastic agents are reviewed.
Journal ArticleDOI
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova,Irina Vetter +1 more
TL;DR: This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.
References
More filters
Journal ArticleDOI
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Bart Barlogie,Guido Tricot,Elias Anaissie,John D. Shaughnessy,Erik Rasmussen,Frits van Rhee,Athanasios Fassas,Maurizio Zangari,Klaus Hollmig,Mauricio Pineda-Roman,Choon Kee Lee,Giampaolo Talamo,Raymond Thertulien,Elias Kiwan,Somashekar G. Krishna,Michele Fox,John Crowley +16 more
TL;DR: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival.
Journal ArticleDOI
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
Paul G. Richardson,Hannah R. Briemberg,Sundar Jagannath,Patrick Y. Wen,Bart Barlogie,James R. Berenson,Seema Singhal,David S. Siegel,David Irwin,Michael W. Schuster,Gordan Srkalovic,Raymond Alexanian,S. Vincent Rajkumar,Steven A. Limentani,Melissa Alsina,Robert Z. Orlowski,Kevin Najarian,Dixie Lee Esseltine,Kenneth C. Anderson,Anthony A. Amato +19 more
TL;DR: Bortezomib-associated peripheral neuropathy seemed reversible in the majority of patients after dose reduction or discontinuation, and the overall occurrence was independent of baseline neuropathy or type of prior therapy.
Journal ArticleDOI
Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies
TL;DR: New evidence strongly suggests that intravenous calcium and magnesium therapy can attenuate the development of oxaliplatin-induced CIPN, without reducing treatment response, and accumulating data suggest that vitamin E may also attenuateThe development of CIPn.
Journal ArticleDOI
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
Andrew D. Seidman,Donald A. Berry,Constance Cirrincione,Lyndsay Harris,Hyman B. Muss,P. Kelly Marcom,Grandella Gipson,Harold J. Burstein,D. Lake,Charles L. Shapiro,Peter Ungaro,Larry Norton,Eric P. Winer,Clifford A. Hudis +13 more
TL;DR: In this article, trastuzumab was demonstrated to improve outcomes of paclitaxel therapy for human epidermal growth factor receptor-2 (HER-2)-positive patients, and was therefore incorporated.
Journal ArticleDOI
Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
Ethan Basch,Alexia Iasonos,Tiffani L McDonough,Allison Barz,A. Culkin,Mark G. Kris,Howard I. Scher,Deborah Schrag +7 more
TL;DR: Patient reporting of symptoms could add to the current approach to symptom monitoring in cancer treatment trials, and the use of real-time collection of patient-reported outcomes for early detection of potentially serious adverse events.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more